Houston、TXにおける膠腫の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、膠腫に関する23件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
被験者募集中第1/2相
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Baylor College of Medicine, Houston
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
被験者募集中第1相
- M D Anderson Cancer Center, Houston
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
被験者募集中第2相
- Texas Children's Hospital, Houston
MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
被験者募集中
- M D Anderson Cancer Center, Houston
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
被験者募集中第1相
- The University of Texas M. D. Anderson Cancer Center, Houston
Targeted Pediatric High-Grade Glioma Therapy
被験者募集中観察研究
- Texas Children's Hospital, Houston
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Study of Olutasidenib and Temozolomide in HGG
被験者募集中第2相
- Texas Children's Hospital, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- MD Anderson Cancer Center, Houston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
被験者募集中第2相
- Texas Children's Hospital, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
被験者募集中観察研究
- M D Anderson Cancer Center, Houston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Houston
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第1相
- Excel Diagnostics & Nuclear Oncology Center, Houston
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
被験者募集中第1相
- Texas Children's Hospital, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- University of Texas MD Anderson Cancer Center, Houston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
被験者募集中早期第1相健康なボランティア歓迎
- Texas Children's Hospital, Houston
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
被験者募集中早期第1相
- M D Anderson Cancer Center, Houston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
被験者募集中第2相
- Texas Children's Hospital, Houston
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
被験者募集中早期第1相
- Texas Children's Hospital, Houston
他の都市における膠腫の試験
- New York City, NY25件の研究
- Boston, MA20件の研究
- Washington, DC19件の研究
- Philadelphia, PA16件の研究
- Columbus, OH15件の研究
- Miami, FL15件の研究
- San Francisco, CA14件の研究
- Chicago, IL13件の研究
- Durham, NC12件の研究
- Seattle, WA11件の研究
- Los Angeles, CA10件の研究
- St. Louis, MO10件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。